A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients

Summary

A Phase II Study of AUY922, Novel HSP Inhibitor, in Patients with Advanced GIST Failed to or Intolerance of Imatinib and Sunitinib Therapy Primary endpoint: •The primary endpoint of this study is to assess disease control rate (complete response + partial response + stable disease≧4 months) of AUY922 in patients with advanced GIST failed to imatinib and sunitinib Secondary endpoints: * To determinate the objective response rate (ORR, complete response + partial response) * To determinate the time to tumor progression (TTP) * To evaluate the safety and toxicity profiles of AUY922 * To evaluate the pharmacokinetics profile of AUY922 in Taiwan GIST population * To access the pharmacodynamic effect of AUY922 on HSP client proteins in blood and tumor if feasible , i.e. HSP70, in Taiwan GIST population * To access the tissue biomarkers pre-treatment and 4wks post treatment if feasible, i.e. HSP70, c-KIT, PDGFRA mutation, ...etc in Taiwan GIST population Exploratory endpoints: •PET imaging; sSUVmax

Timeline

Start

2011-10

Primary completion

2015-05

Completion

2019-10

Drugs

Indications